PMID- 16538540
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20141120
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 98
IP  - 1
DP  - 2006 Jul
TI  - Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct 
      phenotype.
PG  - 99-108
AB  - PURPOSE: The significance of HER-2/neu results obtained by immunohistochemical 
      analyses (IHC) which are neither negative nor strongly positive is controversial. 
      The incidence of fluorescence in situ hybridization (FISH) positivity in these 
      tumors is small and the implication is that these borderline results represent 
      laboratory misclassification. We analyzed the tumor characteristics of these 
      HER-2/neu borderline tumors to determine if they represent a unique tumor type. 
      METHODS: HER-2/neu status was determined by image analysis (IA) of IHC sections 
      in 669 cases of invasive breast cancer. Borderline cases were reflexed to FISH to 
      determine gene status. HER-2/neu results were compared to tumor morphology and 
      other tumor markers. RESULTS: HER-2/neu was negative, borderline and positive in 
      69.5, 15.8, and 14.6% of cases, respectively. HER-2/neu amplification was present 
      in 17.3% of borderline cases. The borderline group is significantly different 
      from the HER-2/neu positive group for all parameters studied except Ki-67. 
      Compared to the HER-2/neu negative group, the borderline group showed a 
      significantly higher HER-2/neu gene copy number and a trend towards lower 
      progesterone receptor expression (p=0.058). Compared to the HER-2/neu negative 
      group, the HER-2/neu borderline/FISH-negative group showed significantly lower PR 
      expression. Compared to the HER-2/neu positive group, the HER-2/neu 
      borderline/FISH positive group showed significant differences with multiple 
      parameters. CONCLUSION: Borderline HER-2/neu tumors are a unique tumor type and 
      do not represent laboratory imprecision. Hormone receptor alterations are 
      associated with early changes in HER-2/neu expression. While IA is capable of 
      detecting these changes, current FISH methodology is not.
FAU - Killeen, Jeffrey L
AU  - Killeen JL
AD  - Department of Pathology, Kapiolani Medical Center for Women and Children, John A. 
      Burns School of Medicine, University of Hawaii, Honolulu, Hawaii 96826, USA. 
      Jeffrey.Killeen@hawaiilabs.com
FAU - Ortega-Lopez, Anna
AU  - Ortega-Lopez A
FAU - Shaha, James
AU  - Shaha J
FAU - Shaha, Steven H
AU  - Shaha SH
FAU - Fu, Jennifer B
AU  - Fu JB
LA  - eng
PT  - Journal Article
DEP - 20060315
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*metabolism/*pathology
MH  - Carcinoma/*metabolism/*pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Phenotype
MH  - Receptor, ErbB-2/*biosynthesis/chemistry
EDAT- 2006/03/16 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/03/16 09:00
PHST- 2005/12/02 00:00 [received]
PHST- 2005/12/05 00:00 [accepted]
PHST- 2006/03/16 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/03/16 09:00 [entrez]
AID - 10.1007/s10549-005-9136-1 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2006 Jul;98(1):99-108. doi: 10.1007/s10549-005-9136-1. 
      Epub 2006 Mar 15.